Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure

Eur J Clin Pharmacol. 1985;28(6):637-40. doi: 10.1007/BF00607907.

Abstract

The inhibitory effect of omeprazole on gastric acid secretion was tested in a group of patients on haemodialysis for chronic renal failure. Single 30 mg doses almost totally inhibited basal acid output on both dialysis and non-dialysis days. Plateau acid output was reduced by a mean of 77% and 90% on non-dialysis and dialysis days respectively. The absorption and pharmacokinetic profile of omeprazole were not affected by dialysis. Omeprazole was not recoverable from dialysis fluid. It is concluded that omeprazole is a potent inhibitor of gastric acid secretion in patients with chronic renal failure, and its effect is not influenced by haemodialysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Ulcer Agents / metabolism*
  • Anti-Ulcer Agents / pharmacology
  • Benzimidazoles / metabolism*
  • Benzimidazoles / pharmacology
  • Duodenal Ulcer / etiology
  • Duodenal Ulcer / prevention & control
  • Gastric Acid / metabolism*
  • Humans
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / metabolism*
  • Kinetics
  • Male
  • Middle Aged
  • Omeprazole
  • Renal Dialysis

Substances

  • Anti-Ulcer Agents
  • Benzimidazoles
  • Omeprazole